Illumina, Inc. (ILMN)
After hours:
| Previous close | 216.95 |
| Open | 216.89 |
| Bid | 220.00 x 1000 |
| Ask | 224.00 x 1000 |
| Day's range | 214.24 - 220.44 |
| 52-week range | 173.45 - 371.16 |
| Volume | |
| Avg. volume | 1,342,981 |
| Market cap | 34.606B |
| Beta (5Y monthly) | 1.13 |
| PE ratio (TTM) | 51.40 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Financial Times
Carl Icahn says Illumina directors demanded extra insurance for Grail deal
Carl Icahn has alleged Illumina directors demanded the company buy them extra personal liability insurance before they agreed to close its $8bn purchase of cancer screening company Grail against the wishes of regulators. Icahn has engaged in a proxy battle with the company over what he describes as its “disastrous” acquisition of Grail in August 2021. EU authorities raised objections with Illumina over its proposed acquisition of Grail in September 2020 and were investigating the deal when the company took the unusual step of closing the transaction.
- Zacks
Why Is Seattle Genetics (SGEN) Up 24.6% Since Last Earnings Report?
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Financial Times
Carl Icahn urges Fed to keep fighting inflation ‘disease’ after SVB collapse
Activist investor Carl Icahn has urged the Federal Reserve to stay the course in the fight against the “disease of inflation” despite the failure of Silicon Valley Bank and two other banks last week. “I think you have to stamp out the disease of inflation,” Icahn told the Financial Times. Icahn’s comments come ahead of the Fed’s rate-setting meeting next week, with economists actively debating whether it will raise interest rates by 0.25 percentage points or take a pause following the SVB implosion.
